EE04047B1 - Sidovudiini, 1592U89 ja 3TC või FTC sünergistlikud kombinatsioonid - Google Patents

Sidovudiini, 1592U89 ja 3TC või FTC sünergistlikud kombinatsioonid

Info

Publication number
EE04047B1
EE04047B1 EE9700240A EE9700240A EE04047B1 EE 04047 B1 EE04047 B1 EE 04047B1 EE 9700240 A EE9700240 A EE 9700240A EE 9700240 A EE9700240 A EE 9700240A EE 04047 B1 EE04047 B1 EE 04047B1
Authority
EE
Estonia
Prior art keywords
ftc
zidovudine
synergistic combinations
synergistic
combinations
Prior art date
Application number
EE9700240A
Other languages
English (en)
Estonian (et)
Other versions
EE9700240A (et
Inventor
Walter Barry David
Heider St. Clair Martha
Original Assignee
The Wellcome Foundation Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE04047(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9506490.3A external-priority patent/GB9506490D0/en
Priority claimed from GBGB9506489.5A external-priority patent/GB9506489D0/en
Application filed by The Wellcome Foundation Limited filed Critical The Wellcome Foundation Limited
Publication of EE9700240A publication Critical patent/EE9700240A/xx
Publication of EE04047B1 publication Critical patent/EE04047B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
EE9700240A 1995-03-30 1996-03-28 Sidovudiini, 1592U89 ja 3TC või FTC sünergistlikud kombinatsioonid EE04047B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9506490.3A GB9506490D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
GBGB9506489.5A GB9506489D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
PCT/EP1996/001352 WO1996030025A1 (en) 1995-03-30 1996-03-28 Synergistic combinations of zidovudine, 1592u89 and 3tc or ftc

Publications (2)

Publication Number Publication Date
EE9700240A EE9700240A (et) 1998-04-15
EE04047B1 true EE04047B1 (et) 2003-06-16

Family

ID=26306774

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9700240A EE04047B1 (et) 1995-03-30 1996-03-28 Sidovudiini, 1592U89 ja 3TC või FTC sünergistlikud kombinatsioonid

Country Status (35)

Country Link
US (1) US6417191B1 (2)
EP (1) EP0817637B1 (2)
JP (1) JP2954357B2 (2)
KR (1) KR100542536B1 (2)
CN (1) CN1103593C (2)
AP (1) AP652A (2)
AT (1) ATE220551T1 (2)
AU (1) AU715213B2 (2)
BR (3) BR9607851B1 (2)
CA (1) CA2216634C (2)
CZ (1) CZ295940B6 (2)
DE (3) DE122005000029I1 (2)
DK (1) DK0817637T3 (2)
EA (1) EA000626B3 (2)
EE (1) EE04047B1 (2)
ES (1) ES2179193T3 (2)
FR (1) FR05C0022I2 (2)
GE (1) GEP20022647B (2)
HU (1) HU224010B1 (2)
IL (1) IL117727A (2)
LU (1) LU91171I2 (2)
MX (1) MX9707316A (2)
MY (1) MY115461A (2)
NL (1) NL300195I2 (2)
NO (2) NO313787B1 (2)
NZ (1) NZ306419A (2)
OA (1) OA10616A (2)
PL (1) PL187085B1 (2)
PT (1) PT817637E (2)
RO (1) RO117995B1 (2)
SI (1) SI0817637T1 (2)
SK (1) SK283825B6 (2)
TR (1) TR199701074T1 (2)
UA (1) UA60293C2 (2)
WO (1) WO1996030025A1 (2)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU727983B2 (en) * 1996-06-25 2001-01-04 Glaxo Group Limited Combinations comprising VX478, zidovudine, FTC and/or 3TC for use in the treatment of HIV
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
GB9709945D0 (en) * 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
AU769660B2 (en) * 1997-05-17 2004-01-29 Glaxo Group Limited Carbocyclic nucleoside hemisulfate and its use in treating viral infections
AR012702A1 (es) * 1997-05-17 2000-11-08 Glaxo Group Ltd Combinacion de (-)-(1s,4r)-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il]- 2-ciclopenteno-1-metanol y un inhibidor dee transcriptasa reversa no nucleosidouna formulacion farmaceutica que comprende la combinacion, su uso medico en terapia para tratar la infeccion de vih, y un empaque para el paciente
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
WO1999060988A2 (en) * 1998-05-29 1999-12-02 University Of Florida Combination therapy for treatment of fiv infection
US6875773B1 (en) 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
GB9820417D0 (en) * 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
US6432966B2 (en) 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
AP2220A (en) * 2001-05-11 2011-03-24 Cipla Medpro Pty Ltd Pharmaceutical composition.
AR040242A1 (es) * 2002-06-04 2005-03-23 Glaxo Group Ltd Composiciones farmaceuticas
KR100860136B1 (ko) 2003-01-14 2008-09-25 길리애드 사이언시즈, 인코포레이티드 복합 항바이러스 치료를 위한 조성물 및 방법
BRPI0408704A (pt) 2003-03-24 2006-03-07 Hoffmann La Roche benzil-piridazinonas como inibidores de transcriptase reversa
WO2005040816A1 (en) 2003-10-24 2005-05-06 Immunaid Pty Ltd Method of therapy
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
WO2007045573A1 (en) 2005-10-19 2007-04-26 F. Hoffmann-La Roche Ag Phenyl-acetamide nnrt inhibitors
JP5415957B2 (ja) 2006-12-13 2014-02-12 エフ．ホフマン−ラ ロシュ アーゲー 非ヌクレオシド逆転写酵素阻害剤としての２−（ピペリジン−４−イル）−４−フェノキシ−又はフェニルアミノ−ピリミジン誘導体
PL2120878T3 (pl) * 2007-02-09 2015-01-30 Alphapharm Pty Ltd Postać dawkowania zawierająca dwa czynne składniki farmaceutyczne o różnych postaciach fizycznych
HUE026456T2 (en) 2009-05-27 2016-05-30 Biotempus Ltd Methods of treating diseases
LT2932970T (lt) 2010-01-27 2018-06-25 Viiv Healthcare Company Antivirusinė terapija
CA2918707A1 (en) 2013-08-29 2015-03-05 Teva Pharmaceuticals Industries Ltd. Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir
EP3129009A1 (en) 2014-04-08 2017-02-15 Teva Pharmaceutical Industries Ltd Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
AU2015303835B2 (en) 2014-08-12 2020-04-09 Monash University Lymph directing prodrugs
US11738087B2 (en) 2015-09-08 2023-08-29 Monash University Lymph directing prodrugs
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
EP4306524A3 (en) * 2017-08-29 2024-09-11 PureTech LYT, Inc. Lymphatic system-directing lipid prodrugs
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
IL295362A (en) 2020-02-05 2022-10-01 Puretech Lyt Inc Lipid drug inhibitors of neurosteroids

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5122517A (en) 1988-06-10 1992-06-16 Regents Of The University Of Minnesota Antiviral combination comprising nucleoside analogs
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
GB9104740D0 (en) 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
SK279262B6 (sk) 1991-05-16 1998-08-05 Glaxo Group Limited Protivírusová zmes, farmaceutický prostriedok s je
AU4079593A (en) * 1992-05-13 1993-12-13 Wellcome Foundation Limited, The Therapeutic combinations
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
GB9417249D0 (en) 1994-08-26 1994-10-19 Wellcome Found A novel salt
US5869461A (en) 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
DE69718168T2 (de) 1996-06-25 2003-10-23 Glaxo Group Ltd., Greenford Zusammensetzungen enthaltend vx478, zidovudine und 159u89 für die verwendung in der behandlung von hiv
AU727983B2 (en) 1996-06-25 2001-01-04 Glaxo Group Limited Combinations comprising VX478, zidovudine, FTC and/or 3TC for use in the treatment of HIV
DE10226522A1 (de) 2002-06-14 2003-12-24 Degussa Verwendung von Übergangsmetallkomplexen mit stickstoffhaltigen mehrzähnigen Liganden als Bleichkatalysator und Bleichmittelzusammensetzung

Also Published As

Publication number Publication date
CA2216634C (en) 2004-07-20
SI0817637T1 (en) 2002-10-31
IL117727A0 (en) 1996-07-23
BRPI9607851B8 (pt) 2019-11-05
NO974510D0 (no) 1997-09-29
ATE220551T1 (de) 2002-08-15
BRPI9612992B1 (pt) 2020-08-04
NL300195I1 (nl) 2005-08-01
TR199701074T1 (xx) 1998-02-21
FR05C0022I2 (2) 2005-10-21
OA10616A (en) 2001-03-15
KR19980703420A (ko) 1998-11-05
CZ295940B6 (cs) 2005-12-14
CN1185110A (zh) 1998-06-17
EA199700203A1 (ru) 1998-02-26
DK0817637T3 (da) 2002-11-11
CZ309097A3 (cs) 1998-05-13
EP0817637A1 (en) 1998-01-14
DE122005000029I1 (de) 2005-10-06
HK1009401A1 (en) 1999-09-10
EA000626B1 (ru) 1999-12-29
AU715213B2 (en) 2000-01-20
NO2005014I2 (no) 2008-02-11
BR9607851B1 (pt) 2009-01-13
DE122005000029I2 (de) 2006-04-27
NO2005014I1 (no) 2005-06-06
IL117727A (en) 1999-11-30
MX9707316A (es) 1997-11-29
PL187085B1 (pl) 2004-05-31
WO1996030025A1 (en) 1996-10-03
UA60293C2 (uk) 2003-10-15
JP2954357B2 (ja) 1999-09-27
DE69622386D1 (de) 2002-08-22
HUP9801571A2 (hu) 1999-01-28
PL322532A1 (en) 1998-02-02
EA000626B3 (ru) 2016-04-29
NZ306419A (en) 2000-01-28
PT817637E (pt) 2002-11-29
CN1103593C (zh) 2003-03-26
NO313787B1 (no) 2002-12-02
GEP20022647B (en) 2002-03-25
NL300195I2 (nl) 2005-11-01
ES2179193T3 (es) 2003-01-16
SK129597A3 (en) 1998-07-08
BR9607851A (pt) 1998-07-21
AP652A (en) 1998-06-19
RO117995B1 (ro) 2002-12-30
FR05C0022I1 (2) 2005-06-10
LU91171I9 (2) 2018-12-28
LU91171I2 (fr) 2005-07-04
KR100542536B1 (ko) 2006-03-23
HUP9801571A3 (en) 2001-04-28
US6417191B1 (en) 2002-07-09
EP0817637B1 (en) 2002-07-17
MY115461A (en) 2003-06-30
DE69622386T2 (de) 2003-02-13
CA2216634A1 (en) 1996-10-03
NO974510L (no) 1997-09-29
SK283825B6 (sk) 2004-02-03
AU5497296A (en) 1996-10-16
HU224010B1 (hu) 2005-04-28
AP9701089A0 (en) 1997-10-31
JPH10511682A (ja) 1998-11-10
EE9700240A (et) 1998-04-15

Similar Documents

Publication Publication Date Title
EE9700240A (et) Sidovudiini, 1592U89 ja 3TC või FTC sünergistlikud kombinatsioonid
EE03741B1 (et) N-propargüül-1-aminoindaani R-enantiomeeri, sellesoolade ja kompositsioonide kasutamine
DK0871656T3 (da) Dolastatinderivater, deres fremstilling og anvendelse
FI964311L (fi) Bifunktionaalinen proteiini, valmistus ja käyttö
FI962879L (fi) Sinkkisormiproteiinijohdannaisia ja niiden menetelmiä
FI960889A7 (fi) Naftyyliyhdisteitä, välituotteita, koostumuksia ja menetelmiä
EE04500B1 (et) Trombiini inhibiitorid, nende saamine ja kasutamine
FI952158L (fi) Hiihtokäsine ja hihtosauva sekä niiden yhdistelmä
NO986034D0 (no) Kombinasjoner omfattende VX 478, ZidovudÞn, FTC og/eller 3TC for anvendelse
DK0840548T3 (da) Synergistisk, herbicid sammensætning samt fremgangsmåde til fremstilling deraf
FI972988L (fi) Menetelmiä ja farmaseuttisia koostumuksia, joissa käytetään desmetyyliselegiliiniä
DK60893D0 (da) Piperidinderivater, deres fremstilling og anvendelse
EE9800451A (et) Uued imidasotriasolopürimidiinid, nende valmistamismeetod ja kasutamine ravimainetena
FI952738L (fi) Stabiiliproteiini, fosfolipidikoostumuksia ja menetelmiä
PT826679E (pt) Compostos de naftilo intermediarios composicoes e metodos de utilizacao
BR9610382A (pt) Composição de tratamento do cableo
FI972965A7 (fi) Uusia peptidejä, niiden valmistus ja käyttö
NO972821D0 (no) 1-C-perfluoralkylglycosider, deres fremstilling og anvendelse
FI964446L (fi) Uusia tetrapeptidejä, niiden valmistus ja käyttö
FI965172A7 (fi) Uusia amido-kinoksaliinidioneja, niiden valmistus ja käyttö
PT101949A (pt) Boneco com elevacao simultania de bracos, pernas e abertura de olhos
FI942331L (fi) Biosidisia koostumuksia ja niiden käyttö
FI970497A0 (fi) Arrangemang foer raeddningsvaeg i en byggnad med flera vaoningar
ITRM950305A0 (it) Composizione cosmetica ad azione dermoprotettiva e dermonutritiva.
BR9502585A (pt) Treliças de bambu

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

FG1Y Spc granted

Free format text: PRODUCT NAME: KIVEXA; NAT. REGISTRATION NO/DATE: C(2004)5373 20041217; FIRST REGISTRATION: EU/1/04/298/001-002

Spc suppl protection certif: C20050002 00007

Filing date: 20050512

Extension date: 20191217

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231

SPCM Correction and amendment to the data concerning application for a supplementary protection certificate

Spc suppl protection certif: C20050002 00007

Extension date: 20191222

SPCX Term of validity of supplementary protection expired

Spc suppl protection certif: 00007

Extension date: 20211209